Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Noiiglutide

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Hengrui · Phase 2 · Completed · Enrollment 128

NCT03848793

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
HS-20004 or placebo treatment (Low dose)n/rn/rn/rn/r
HS-20004 or placebo treatment (median dose 1)n/rn/rn/rn/r
HS-20004 or placebo treatment (median dose 2)n/rn/rn/rn/r
HS-20004 or placebo treatment (high dose)n/rn/rn/rn/r

Not shown

  • HS-20004 or placebo treatment (Low dose): endpoint not reported
  • HS-20004 or placebo treatment (median dose 1): endpoint not reported
  • HS-20004 or placebo treatment (median dose 2): endpoint not reported
  • HS-20004 or placebo treatment (high dose): endpoint not reported